Clin2
NCT05853718Possibly a fitRecruiting

Tenofovir treatment for hepatitis B during pregnancy

Chronic Hepatitis bTenofovir Alafenamide Fumarate

Treatments studied

Part of Digestive system, Infections clinical trials.

This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
50 people
Ages
20 years to 40 years
Study type
Interventional

Who can take part

  • You are 20 to 40 years old and currently pregnant
  • Your blood tests show active hepatitis B (HBsAg positive and HBeAg positive)
  • Your HBV DNA level is higher than 200,000 IU/mL between weeks 24 and 32
  • You are willing to take TAF to reduce mother-to-child transmission and you can get consent from both partners
  • You do not have hepatitis C or HIV, or other major chronic illnesses

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07169656Recruiting
Study on reducing liver cancer risk in hepatitis B patients

This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.

Anyang
NCT06707922Enrolling by invitation
Long-term follow-up for hepatitis B treatment

This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.

Beijing
NCT07542951Enrolling by invitation· Phase 4
TAF vs TDF antiviral treatment during pregnancy for hepatitis B

This study compares two antiviral medications (TAF and TDF) in pregnant women with hepatitis B to see which is safer and more effective during pregnancy and for the baby's health.

Guangzhou, Guangdong
NCT05403047Recruiting· Phase 4
Preventing mom-to-baby hepatitis B with tenofovir

This study tests whether the medicine tenofovir disoproxil can help prevent passing hepatitis B from mother to baby during pregnancy. It is for pregnant women with an active hepatitis B infection who are early in their pregnancy (less than 24 weeks).

Tokonbéré
NCT06947356Recruiting
TAF vs TDF to prevent passing hepatitis B to babies

This trial tests if TAF is safer and as effective as TDF for pregnant women with high hepatitis B viral loads to prevent passing the virus to their babies. You may qualify if you are pregnant, between 20-28 weeks, and have high viral levels.

Guangzhou, Guangdong
NCT07668934Enrolling by invitation· Phase 4
TAF for early and middle pregnancy with chronic hepatitis B

This trial tests a hepatitis B medicine called TAF in pregnant women who need antiviral treatment. It helps protect both mom and baby from complications of the virus.

Guangzhou, Guangdong

Hear when a new Chronic Hepatitis B trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.